Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.
Cancer immunotherapy has firmly moved from the realm of the boutique to the routine, and the dramatic and durable responses it may produce continue to impress. The use of monoclonal antibodies to block immune regulatory checkpoints demonstrates benefit across multiple cancer types; however, limitations exist as only a fraction of patients respond to therapy, and optimal predictors of response are lagging behind clinical development.
An effective anti-tumor immune response requires recognition of tumor cells by appropriate effector immune elements and a tumor microenvironment (TME) that is permissive to cytolytic T cell activity. Tumor cell recognition is predicated on the concept that cellular immune responses can develop against cancer-specific antigens that arise from cancer-specific mutations. Accordingly, genomic analyses of several tumor types exposed to CTLA-4 or PD-1 blocking agents confirm that mutational burden predicts response (Hugo et al., 2016; Snyder et al., 2014) and that tumor-specific mutant antigens are the key target (Gubin et al., 2014) . By extension, studies of NSCLC samples have shown that due to neoantigen heterogeneity, if clonal neoantigens can be effectively targeted, better anti-tumor responses can result (McGranahan et al., 2016) . Copy number alterations provide additional information, with a higher burden of copy number losses, commonly affecting immunerelated genes, predicting poor response to both CTLA-4 and PD-1 blockade (Roh et al., 2017) .
But knowledge of a tumor's mutational status provides only one part of one side of the story. Expression of immunosuppressive molecules and the presence of immunoregulatory cellular elements adaptively thwart the anti-tumor immune response and are driven by the presence and action of CD8+ T cells (Spranger et al., 2013) . Expression of immune checkpoints themselves (Taube et al., 2014) or evidence of an inflamed TME particularly in early-on-treatment samples (Chen et al., 2016) are arguably betterand simpler-predictors of PD-1 inhibitor response than mutational load across multiple cancer types. While the inhibitory effects of CTLA-4 and PD-1 can be overcome by immunotherapy agents targeting these molecules, therapeutic failure frequently involves upregulation of numerous other, less well-studied, immune inhibitory checkpoint molecules (Koyama et al., 2016) .
In this issue of Cell, new analyses presented by Riaz et al., provide an integrated perspective of how the genomic landscape evolves for both players in the cancer immunity playoff (Riaz et al., 2017) . In this new work, they study the largest yet-reported cohort (n = 68) of genomically interrogated tumor samples from patients receiving the PD-1 blocking agent nivolumab, examining wholeexome, transcriptome, and T cell receptor (TCR) sequencing. Importantly, this cohort includes patients who were previously treated with CTLA-4 blocking antibodies, as well as those who were naive to CTLA-4 blockade, with response rates not being significantly different between these groups (23% versus 32%, respectively). However, differences are noted when genomic profiling is taken into consideration, with a positive association of mutational load and treatment response only becoming clearly evident in patients who were naive to CTLA-4 blockade. This is provocative and further studies are warranted studying the role of mutational load in the setting of concurrent treatment with anti-CTLA-4 and anti-PD-1, as these different forms of immune checkpoint blockade are known to have differential effects on the tumor microenvironment, and there may be less dependence on mutational load in the setting of concurrent therapy.
Another key feature of the analysis performed by Riaz et al. is the longitudinal assessment of the tumor and associated immune infiltrate in the context of treatment with anti-PD-1 therapy. The studies confirm the utility of dynamic on-treatment tumor assessment in the setting of treatment with anti-PD-1 therapy (Chen et al., 2016) , revealing a richer but nonetheless thematically similar repertoire of changes reflecting effective activation of immune responses and compensatory upregulation of additional immune checkpoint molecules in responders to therapy. Importantly, the studies also reveal evidence of immunoediting in responders to anti-PD-1 therapy (Figure 1 ). This ''clonal co-evolution'' of both tumor and immune repertoire has been studied in the setting of treatment with chemotherapy and stem cell transplant for liquid tumors such as chronic lymphocytic leukemia; however, it has not been well defined in the context of immune checkpoint blockade for solid tumors.
An intriguing question raised through such studies is what the nature of the competition is between immunogenicity and clonality of neoantigen mutations. Clonal neoantigens certainly offer the prospect of more widespread tumor cell elimination but are immunogenic antigens more commonly ''doomed'' to be subclonal, simply because immunogenic clonal neoantigens would be less likely to survive to the stage of clinical diagnosis? And if stepwise or cytoreductive (sub) clonal elimination suggests that there are asymptotic limits on immunotherapy efficacy, how is it that some patients clearly achieve complete and durable responses?
Despite the outstanding work from this group and others, we are not yet able to claim a comprehensive understanding of the effects of immune checkpoint blockade on both tumors and immune cells at a molecular level, and additional insights are clearly needed. It remains contended how well the biomarkers of CTLA-4 blockade response relate Parallel analysis of tumor mutational composition and TCR sequencing demonstrates a delicate interplay of tumor cell mutational contraction, subclonal evolution, and T cell repertoire sculpting in keeping with concepts of immunoediting and immune checkpoint molecule action. In tumors that fail to respond to anti-PD-1 therapy, tumors (top left) may show persistence of major clones, expansion of sub-clones, adaptive loss of neoantigen expression on some or all cells of previously expressing clones, and emergence of new subclones. The corresponding T cell repertoire (top right) may show failure to recruit/expand tumorspecific T cell clones and upregulation of inhibitory checkpoint molecule expression, resulting in incomplete elimination of tumor (sub)clones. In tumors that respond to anti-PD-1 therapy (bottom left), subclonal tumor cell elimination-most characteristically of mutational subclones that uniformly express and present immunogenic mutational products-is accompanied by overall mutational contraction. However, major clones and neoantigen non-expressing tumor cells may persist. Corresponding T cell repertoires (bottom right) may demonstrate release from inhibitory checkpoints and expansion of (pre-existing) tumor-specific T cell clones, relative loss of tumor-non-specific or ineffective T cell clones, and an associated decrease in TCR diversity measures.
to PD-1 blockade response, and the effects of treatment sequence, with potential immune-sculpting effects on subsequent therapies, are increasingly evident. Furthermore, numerous checkpointmolecule-targeting strategies, whether they be blockade of inhibitory molecules or activation of stimulatory ones, are in development; it remains unknown whether the lessons learned from detailed study of existing immune checkpoint blockade-treated patients will transfer to these newer agents. Finally, it is becoming increasingly apparent that factors outside of the tumor and microenvironment (such as the overall host immune status and the gut microbiome) may influence therapeutic responses, and these factors must be taken into consideration in a more holistic approach to cancer therapy. Nonetheless, significant gains are being made through such integrated approaches as those presented herein.
Innate lymphoid cells (ILCs) are tuned to quickly respond to and amplify tissue-specific signals. Work of three independent groups in Nature uncovers a novel mode of inflammatory communication between ILC2s and neurons at mucosal surfaces.
Innate lymphoid cells (ILCs) are an evolutionarily ancient cell population and are highly enriched in mucosal tissues. Recent work has demonstrated that ILCs play a pivotal role in mediating tissue repair as well as coordinating immune responses (Klose and Artis, 2016) . Like helper T cells, ILC subsets exhibit remarkable diversity, allowing them to coordinate immune programs somewhat tailored to viruses or bacteria (groups 1 and 3) and parasites or allergens (group 2). A regulatory T cell-related ILC (ILCreg) was also recently described (Wang et al., 2017) . Despite their key role in inflammatory processes, ILCs in mice lack receptors capable of recognizing antigen diversity. Instead, ILCs act as selective immune amplifiers, integrating secreted signals from multiple cell types to enhance tissue responses. For example, specialized epithelial cells that monitor the intestinal lumen, termed tuft cells, can augment a type 2 immune response to a worm infection through IL-25 alarmin secretion that activates ILC2s (von Moltke et al., 2016) . These observations raise questions about whether other cell types typically tuned to survey mucosal surfaces could signal to ILCs. Neurons and glia in particular are ideally positioned to respond to changes in the mucosal environment (Veiga-Fernandes and Mucida, 2016) . Prior studies have pointed to a homeostatic (Ibiza et al., 2016) and inflammatory role (Talbot et al., 2015) of nervous system input to ILCs in mucosal tissues, suggesting that this interaction may be a key component of mucosal immunity.
In two recent issues of Nature, work from Cardoso et al., Klose et al., and Wallrapp et al. aimed at defining new signaling pathways capable of controlling mucosal group 2 innate lymphoid cells (ILC2s). To probe modulatory inputs to ILC2s, the three independent research groups sequenced different populations of ILCs in mice. Both bulk (Cardoso et al., 2017; Klose et al., 2017) and single-cell (Wallrapp et al., 2017 ) RNA sequencing of ILC subsets led to the discovery that ILC2s in the lungs and intestine selectively express Nmur1, a
